News

Joining a minimalistic wave in pharma marketing, Novo said the change increases memorability and relevance.

Novo Nordisk A/S (NYSE:NVO) has received approval in China for Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH), making it the first GLP-1 receptor agonist approved in the country for the liver disease. The approval expands Wegovy’s potential beyond weight management and cardiovascular benefits into another major condition linked to obesity. Reuters noted that Novo sees […]

Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The Danish drugmaker unveiled a new name, slogan, and set of cultural principles as it trails Eli Lilly in the obesity drug market

Novo Nordisk (NYSE:NVO) announced a corporate rebranding initiative under which it will use “Novo” as its everyday operating name while retaining Novo Nordisk A/S as its legal global company name. The pharmaceutical company also introduced a new tagline, “Lasting Health Starts Now,” alongside a cultural framework called “The Novo Way.

Eli Lilly shed billions in market value over the past month while its underlying business kept breaking records, and now one major Wall Street firm sees a setup that almost never appears in a stock this dominant.

Danish pharmaceuticals giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Monday a name change to just Novo, hoping it will be more "memorable and relevant" for clients.It will keep the full Novo Nordisk as its legal corporate name, using Novo and an updated version of its bull logo for its packaging.

The drugmaker said its new name aims to make it more recognizable to compete in the market for obesity medications.

NVO has fallen about 12% in 2026 after losing more than half its value in 2025, its worst year since 1984.

Novo Nordisk is shortening its name as part of an effort to boost its appeal to consumers in the obesity drug market, where the Danish drugmaker...

One date in the next decade is quietly doing all the work in Wall Street’s newest bear case.

Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.

Novo Nordisk A/S (NYSE:NVO) looks to open a new growth avenue for its blockbuster obesity drug Wegovy by targeting the pediatric market. In the late-stage STEP Young trial, semaglutide (the active ingredient in Wegovy) produced strong results in young children. In the trial, 40.4% of children treated with semaglutide were no longer classified as having […]

Heart disease remains humanity’s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.

Morgan Stanley sees Eli Lilly taking share before semaglutide's patents even become the bigger issue.

The worst may be in the rearview mirror for the drugmaker.

Morgan Stanley Cuts Novo Nordisk to Underweight as Semaglutide Risks Cloud Outlook

European equities traded in the US as American depositary receipts were trending higher late Friday

Morgan Stanley keeps Novo price target at 250 DKK

Investing.com -- JPMorgan revealed Friday that it has started coverage of Hims & Hers Health at Neutral, setting a December 2027 price target of $32 as it weighs the direct-to-consumer health platform's rapid growth against execution risks in its shift to branded weight-loss drugs.

Markets are bracing for Friday's CPI data after a brutal week of selling across stocks, bonds, and crypto, and Wall Street analysts are already reshuffling their ratings on names like Dell, Shopify, Novo Nordisk, and Fortinet before the dust settles.

Morgan Stanley downgraded Novo to ‘Underweight’ from ‘Equal Weight’ while keeping its $40 price target, a 7% downside from current levels.

Novo Nordisk (NVO) closed the most recent trading day at $44.01, moving 1.23% from the previous trading session.

The approval extends semaglutide beyond obesity, but Novo disclosed neither launch timing nor incremental revenue.

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this pharmaceutical giant still has meaningful upside left.

This company aims to serve a market heading toward $100 billion.

Novo Nordisk A/S (NYSE:NVO) has moved one step closer to bringing its oral Wegovy treatment to China after the country’s drug regulator accepted the company’s marketing application. The filing gives Novo an opportunity to expand its weight-management business in the world’s second-largest pharmaceutical market, where demand for GLP-1 therapies is expected to grow substantially. However, […]

PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.